PHP28 Point Of Care Tests: The Long And Winding Road To Reimbursement In The United States And Canada  by Hogue, S. et al.
A14  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
label comparators requested) between 2008 and 2013 for not being cost-effective, 
thereby indirectly recommending the off-label alternative. ConClusions: NICE 
have rejected new interventions in favour of off-label comparators. However, there 
may be a recent shift towards more manufacturers choosing not to compare to the 
requested off-label comparator and for NICE to accept this decision.
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objeCtives: Market access for innovative new technologies can be complex and 
time consuming. As cost-containment pressures intensify, evidentiary hurdles to 
justify new point-of-care (POC) tests continue to grow. Decentralized health care 
decision making also can be a significant hurdle. This study aimed to characterize 
the process and identify challenges for health technology assessment (HTA), pric-
ing, reimbursement, and market access for a new POC test in the United States (US) 
and Canada. Methods: We conducted desktop research of published literature, 
HTA reports, and third-party websites to identify the critical path and data most 
valuable to reimbursement decision making. We also conducted qualitative one-
on-one interviews with payer decision makers in the US (15 payers) and Canada (1 
payer advisor and 2 laboratory directors). Results: Reimbursement is critical to 
rapid adoption of new technologies. There are multiple appropriate access pathways 
for various theatres of care (e.g., outpatient office/clinic, inpatient, emergency), all 
with varying requirements and value drivers. Payment for new diagnostic tests 
typically is handled regionally or locally; treating physicians and medical societies 
can influence these budget decisions. Test reimbursement processes may differ for 
inpatient versus outpatient use. Currently, the evidence hurdle for a POC test is not 
as high as for prescription medicines. ConClusions: Market access for a POC test 
is variable; adequate data to meet decision makers’ needs is not well understood. 
No roadmap exists for navigation of the critical path for POC tests, and evidence 
requirements in the US and Canada are not well established. Access for a POC test 
will be complex; regardless of pathway, decisions regarding reimbursement and 
adoption of new technology are diverse and dispersed across and within countries 
with varying levels of required evidence.
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objeCtives: External reference pricing (ERP) is one of the most common cost-
containment tools used to reduce prices for in-patent pharmaceuticals in European 
Union Member States. The objective of this project was to assess the real life impact 
of ERP in Europe using a simulation model. Methods: A simulation model (devel-
oped for the EU Commission) was built to simulate the evolution of drug price over 
time through the ERP process. Real-life cases of medicinal products were randomly 
selected from medicines approved via the European Medicines Agency centralised 
procedure between 2000 and 2012 and including off-patent/in-patent drugs, cheap/
medium-priced/expensive drugs, and orphan/non orphan drugs. IMS price database 
was selected as source of information, covering 26 European countries and includ-
ing 12 years history price data. Model outcomes were compared to actual recorded 
prices and interpretation of outcomes was enlightened with the French and Scottish 
Health Technology Assessment (HTA) reviews. Results: Fifty three medicines were 
selected for the analysis of real-cases. The following trends were observed: 1) When 
a product was initially recognized as an innovative product by HTA, actual price of 
this product appeared to consistently achieve a higher price than the ERP model 
price; 2) Actual price of the product tended to become lower than ERP model price 
over time when a product had extension of indications over time and generated 
high revenue; 3) Low GDP countries tended to be the last to achieve drug entry, 
suggesting the use of launch sequence strategy from the marketing authorization 
holder. ConClusions: The ERP model seemed to well predict actual prices. ERP 
seems to be modulated by drug innovation as acknowledged by HTA. More research 
is needed to understand the role of launch sequence for price optimization.
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objeCtives: “Device Lag” is one of the most imminent issues for medical device 
industry to focus for the coming years. In order to effectively approach this struc-
tured problem, the recognition of related facts and figures are the key factors. 
The purpose of this research is to provide the analysis of predictability difference 
among medical device categories in US and Japan and its background.  Methods: 
Based on the database of US PMA approved medical devices from 2004 to 2013 and 
new medical devices approved in Japan since April 2007, which point was 3 years 
from the establishment of PMDA (Pharmaceutical and Medical Device Agency) in 
Japan, 260 devices in US and 101 devices in Japan were identified for the analysis 
of predictability. Statistical values related to regulatory review period were com-
pared between US and Japan and also among the device categories. Results: By 
two-sided paired t test New Medical Device regulatory review period (15 devices 
approved in both countries) had no significant difference (P value>0.9).  Among the 
product categories in the United States, for the identification of which the advisory 
committee classification was used, the standard deviation of FDA review time was 
the smallest in the fields of Radiology (202.5 days) followed by Microbiology (211.0 
days) and Pathology (246.6 days) and the largest in the fields of General & Plastic 
market unit and NZ$ shares, and a decline in total NZ$ sales. The second strategy 
resulted in a rapid decline of brand product market unit and NZ$ market shares.
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objeCtives: To evaluate the impacts of two pharmaceutical cost containment 
policies-financial incentive for physicians to reduce their prescription drug expen-
ditures and lump-sum drug price cut implemented in Oct. 2010 and Apr. 2012 respec-
tively- on prescription drug expenditures from 2009 to 2012 in the national health 
insurance system of Korea. Methods: Claims data for outpatient services in a 
random sample of 1,625 clinics were drawn from the national health insurance 
database between 2009 and 2012. Segmented regression analyses of interrupted time 
series were used to evaluate changes in prescription drug expenditures and non-
drug expenditures per claim for selected common diseases – gastric ulcer & gastro-
oesophageal reflux disease (adults), acute upper respiratory infection (URI) (adults/
children), and acute lower respiratory infection (LRI) (adults/children). Results: 
Prescription drug expenditures increased immediately after the implementation 
of financial incentive program in gastric ulcer & gastro-oesophageal reflux disease 
and LRI in adults. Monthly trends of prescription drug expenditures significantly 
decreased after the policy in all diseases analyzed. Lump-sum drug price cut sud-
denly dropped prescription drug expenditures. However, monthly trends of drug 
expenditures significantly increased after that. Neither of the two policies has 
changed the level or trend of non-drug expenditures. ConClusions: Financial 
incentive to physicians for reducing prescription drug costs was associated with 
decreased trends of prescription drug expenditures without increasing non-drug 
expenditures. Drug price cut led to instant reductions of prescription drug expen-
ditures, however, it increased the monthly trends of prescription drug expenditures 
after the sudden reduction. The differential effects of two policies provide implica-
tions for pharmaceutical cost containment strategies in health insurance system.
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objeCtives: Drug shortages are a complex and global phenomenon. When a drug 
cannot be delivered at the moment of patient demand, every stakeholder in the 
health care system is affected. Methods: This study aims to investigate the char-
acteristics, clinical impact, financial impact and management of drug shortages in 
European hospital pharmacies. An online survey was designed based on literature 
and interviews with Belgian pharmacists. The online survey was sent to subscribers 
of Hospital Pharmacy Europe between June and September 2013. Descriptive statis-
tics of the respondent’s answers were calculated. Results: One hundred sixty-one 
respondents were considered in this study. Results show variations between drug 
shortage characteristics in European regions and countries. Besides manufacturing 
problems, a role for European and national policy measures related to the mar-
ket access and trade of pharmaceuticals, such as tendering and parallel trade, are 
discussed as a root cause for drug shortages. Further, respondents indicate drug 
shortages in Europe are associated with clinical risks for patients such as medication 
errors, a financial burden on hospitals and increased workload for the hospital phar-
macy. The median number of hours spent to the management of drug shortages by 
hospital pharmacists was estimated to be 12.85hours/week. While pharmaceutical 
companies and wholesalers already assist the hospital pharmacy in the manage-
ment of shortages, a role is still reserved for the government. ConClusions: This 
study showed drug shortages have a significant effect on hospitals, their personnel 
and patients. Mandatory notification in advance and centralized information is 
proposed to reduce workload for hospital pharmacists. Further, this will allow early 
anticipation of drug shortages and facilitates mitigation of the clinical impact on 
patients. Monitoring of the effect of policy measures on the availability of drugs is 
required to reveal and tackle the root causes behind drug shortages.
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objeCtives: NICE in the UK has a remit to compare new interventions to estab-
lished care, which could include off-label medication. The objective was to update 
the assessment of how frequently NICE request off-label comparators and the sub-
sequent implications. Methods: All NICE single technology appraisal (STA) scopes 
from 01/01/08 to 18/12/13 were reviewed. Off-label comparators were identified 
as those that were being used outside their licence according to the Electronic 
Medicines Compendium. In cases where off-label comparators were requested 
in the scope, the manufacturer’s submission, the Evidence Review Group report 
and the final NICE guidance were reviewed to ascertain the outcome of this 
request. Results: Of 111 completed STAs reviewed, the scopes of 31 (27.9%) 
requested comparison to at least one off-label comparator; the proportion has been 
relatively stable over time. Since the previous analysis at the end of 2012, there 
has been a slight shift to more manufacturers not comparing to the requested 
off-label comparator (51.6% at end 2013 versus 45.8% at end 2012; driven by 80% of 
2013 cases). NICE accepted the decision to not compare to the off-label agent in a 
much higher proportion of appraisals at the end of 2013 (81.3%) versus at the end 
of 2012 (63.6%). Two appraisals where NICE had originally rejected the new technol-
ogy in favour of an off-label comparator had been re-appraised and NICE reversed 
their decision and now recommend the new interventions (TA274 and TA301). 
Overall however, NICE have rejected 8 new interventions (25.8% of scopes with off-
